Efficacy and safety of belimumab in IgA nephropathy: real-world evidence
Nephrology Dialysis Transplantation · 30.10.2026 · 41 (11) · 1999-2007
DOI: 10.1093/ndt/gfag067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 23.03.2026. Verfasst von Manyi Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glomerulonephritis, IGA, Immunosuppressive Agents, Proteinuria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Bethune Charitable Foundation.
Abstract (Originalsprache)
Background
Belimumab, a monoclonal antibody targeting B lymphocyte stimulator, has shown benefits in systemic lupus erythematosus and lupus nephritis, but its role in IgA nephropathy (IgAN) remains unclear. We evaluated the effectiveness and safety of belimumab in IgAN.
Methods
This retrospective cohort study included biopsy-proven IgAN patients at Tongji Hospital, China (July 2020–June 2024). Sixty-nine patients treated with belimumab were compared with 137 propensity score–matched controls receiving standard therapy. The primary outcome was proteinuria remission, defined as a reduction in 24-h urinary protein excretion or urinary protein-to-creatinine ratio (UPCR) to <50% of baseline.
Results
Among 206 patients with IgAN (median age 37 years, baseline estimated glomerular filtration rate 79 ml/min/1.73 m², proteinuria 1.1 g/24 h), 173 (84%) achieved proteinuria remission within 12 months. Remission was higher in the belimumab group: 59% vs 46% at 3 months, 77% vs 66% at 6 months, and 93% vs 80% at 12 months (P = .025 at 12 months), with lower time-averaged UPCR at 6 months [371 (248 738) vs 463(262 855) mg/g] and 12 months [360 (234 560) vs 433(243 720) mg/g, P = .066]. In newly diagnosed patients, remission was significantly higher at 3 months (76.5% vs 47.1%, P = .009) and 6 months (88.2% vs 67.6%, P = .045), with similar trends at later time points. In patients with baseline UPCR >600 mg/g and those receiving RAAS inhibitors, belimumab demonstrated comparable or superior proteinuria reduction. No excess of common adverse events was observed in the belimumab group.
Conclusion
Belimumab treatment was associated with higher proteinuria remission rates in patients with IgAN, without an increased incidence of common adverse events. These findings suggest that belimumab may represent a superior therapeutic approach for IgAN in real-world clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Nephrology, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
- Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Manyi Wu, Chunyu Pan
Förderung
- National Natural Science Foundation of China
- Bethune Charitable Foundation
Zitieren
APA
Wu, M., Cheng, Y., Zhao, X., Cai, X., Pan, C., Qin, B., Zhao, H., Zhang, H., Zhu, H., Zhou, Q., Chang, X., Liu, Q., Xiao, F., Liu, X., Ge, S., Li, J., & Xu, G. (2026). Efficacy and safety of belimumab in IgA nephropathy: real-world evidence. Nephrology Dialysis Transplantation, 41(11), 1999-2007. https://doi.org/10.1093/ndt/gfag067
Vancouver
Wu M, Cheng Y, Zhao X, Cai X, Pan C, Qin B, et al. Efficacy and safety of belimumab in IgA nephropathy: real-world evidence. Nephrology Dialysis Transplantation. 2026;41(11):1999-2007. doi:10.1093/ndt/gfag067
BibTeX
@article{Wu2026,
author = {Wu, Manyi and Cheng, Yichun and Zhao, Xingyang and Cai, Xiaojing and Pan, Chunyu and Qin, Bowen and Zhao, Hairui and Zhang, Hui and Zhu, Han and Zhou, Qiaodan and Chang, Xiaoyan and Liu, Qingquan and Xiao, Fang and Liu, Xiaocheng and Ge, Shuwang and Li, Junhua and Xu, Gang},
title = {Efficacy and safety of belimumab in IgA nephropathy: real-world evidence},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {11},
pages = {1999--2007},
doi = {10.1093/ndt/gfag067}
}
EUVIMED